Biomarkers: Troponin testing--risk stratification to stratified medicine

Area of Science:

• Cardiology
• Diabetology
• Biomarker Research

Background:

• Diabetes mellitus and ischaemic heart disease are significant global health concerns.
• Elevated troponin levels can indicate cardiac injury and portend poor prognosis.
• Identifying high-risk patients is crucial for effective cardiovascular event prevention.

Purpose of the Study:

• To evaluate the utility of high-sensitivity troponin testing in identifying high-risk patients with diabetes and ischaemic heart disease.
• To compare the effectiveness of revascularization versus optimal medical therapy in this patient cohort.

Main Methods:

• Prospective study involving patients with diabetes mellitus and ischaemic heart disease.
• High-sensitivity troponin testing was employed to assess cardiac injury.
• Patients were stratified based on troponin levels and 5-year cardiovascular risk.
• Comparison of outcomes between patients receiving revascularization and those on optimal medical therapy.

Main Results:

• High-sensitivity troponin testing identified 39.3% of patients with elevated troponin levels.
• These patients were found to be at high 5-year risk for cardiovascular death, myocardial infarction, or stroke.
• Revascularization did not demonstrate a significant reduction in ischaemic events compared to optimal medical therapy in the high-troponin group.

Conclusions:

• High-sensitivity troponin assays are effective in risk-stratifying patients with diabetes and ischaemic heart disease.
• Optimal medical therapy appears sufficient for managing ischaemic events in high-risk patients identified by elevated troponin levels.
• Further research may explore personalized treatment strategies for this high-risk population.